Sanofi releases new data on fitusiran
The laboratory announced that the two phase III studies evaluating the fictitious for the prophylactic treatment of hemophilia A or B had met their primary and secondary endpoints. This active ingredient is a small interfering RNA designed to reduce the level of antithrombin, a protein that inhibits blood coagulation. Sanofi should present other results, particularly in terms of dosage, during the year.
Positive opinion from the CHMP for Samsung Bioepis
The CHMP of the EMA issued a favorable opinion concerning the Marketing Authorization ofEpysqli, a biosimilar to Soliris (eculizumab), for the treatment of adults and children with paroxysmal nocturnal hemoglobinuria (PNH). If approved, this drug would become the first hematology biosimilar in Samsung Bioepis. Soliris is a monoclonal antibody owned by AstraZeneca subsidiary Alexion, which sold for $3.8bn in 2022.
VOS INDICES
source
Janssen stops its tests in the RSV
The subsidiary of Johnson & Johnson (J&J) will halt the phase III trial of its vaccine candidate once morest respiratory syncytial virus (RSV) for adults. Janssen justified this decision by a strategic choice aimed at “to prioritize the most transformative assets” of its pipeline. Pfizer, Sanofi or Moderna are developing candidate vaccines once morest this infectious disease, for different types of population, in advanced phases.
Selected for you
